The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of weekly albumin-bound paclitaxel (ab-P) plus weekly cetuximab (Cet) plus intensity-modulated radiation therapy (IMRT) in patients with stage III/IVb head and neck squamous cell carcinoma (HNSCC).
Matthew G. Fury
Research Funding - Celgene
Eric Jeffrey Sherman
No relevant relationships to disclose
Shyam S. Rao
No relevant relationships to disclose
Suzanne L. Wolden
No relevant relationships to disclose
Stephanie Smith-Marrone
No relevant relationships to disclose
Kenneth K. Ng
No relevant relationships to disclose
Boris Mueller
No relevant relationships to disclose
Daphna Y. Gelblum
No relevant relationships to disclose
Pinaki R. Dutta
No relevant relationships to disclose
James Lee
No relevant relationships to disclose
Ronglai Shen
No relevant relationships to disclose
Sarah Kurz
No relevant relationships to disclose
Nora Katabi
No relevant relationships to disclose
Sofia Haque
No relevant relationships to disclose
Nancy Y. Lee
No relevant relationships to disclose
David G. Pfister
No relevant relationships to disclose